Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02340780|
Recruitment Status : Active, not recruiting
First Posted : January 19, 2015
Last Update Posted : February 1, 2018
|Condition or disease||Intervention/treatment||Phase|
|Chronic Lymphocytic Leukemia||Drug: Buparlisib||Phase 2|
Buparlisib has been shown to shrink tumours in animals. It has been studied in some people and seems promising but it is not clear if it can offer better results than standard treatment.
The standard or usual treatment for this disease is chemotherapy, targeted therapy or radiation, either alone or in combination.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia|
|Actual Study Start Date :||January 30, 2015|
|Estimated Primary Completion Date :||June 2018|
|Estimated Study Completion Date :||December 2018|
100mg daily orally every 28 days
- Overall response rate [ Time Frame: 30 months ]To determine the overall response rate (complete + partial response) to oral buparlisib in patients with relapsed and refractory chronic lymphocytic leukemia.
- Number of adverse events in patients [ Time Frame: 30 months ]To evaluate the safety and tolerability of buparlisib administered at 100 mg per day on a 28 day cycle, in patients with previously treated chronic lymphocytic leukemia.
- Efficacy of buparlisib (duration of response rate and progression free survival); composite outcome measure. [ Time Frame: 30 months ]
- To evaluate additional measures of efficacy including duration of response rate and progression free survival
- To explore potential molecular factors which may be prognostic or predictive of response or of relapse.
- To prospectively validate a survival prediction scale.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02340780
|Tom Baker Cancer Centre|
|Calgary, Alberta, Canada, T2N 4N2|
|Cross Cancer Institute|
|Edmonton, Alberta, Canada, T6G 1Z2|
|Winnipeg, Manitoba, Canada, R3E 0V9|
|Canada, Nova Scotia|
|QEII Health Sciences Centre|
|Halifax, Nova Scotia, Canada, B3H 1V7|
|University Health Network|
|Toronto, Ontario, Canada, M5G 2M9|
|The Jewish General Hospital|
|Montreal, Quebec, Canada, H3T 1E2|
|Study Chair:||Sarit Assouline||McGill University - Dept. Oncology, Jewish General Hospital Site, Montreal QC Canada|